Device therapy in heart failure

British Medical Journal

Volumn 335, Issue 7626, 2007, Pages 895-896

  McAlister, Finlay A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BAYES THEOREM; BRADYCARDIA; CARDIAC RESYNCHRONIZATION THERAPY; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DEFIBRILLATOR; DISEASE COURSE; EDITORIAL; EVIDENCE BASED MEDICINE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL STATUS; HEALTH CARE PERSONNEL; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL ADMISSION; HUMAN; INCIDENCE; MEDICAL EXPERT; MEDICAL INSTRUMENTATION; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SINUS RHYTHM; SUDDEN DEATH; SURVIVAL;

DEFIBRILLATORS, IMPLANTABLE; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS;

EID: 35949003583     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39353.546933.BE     Document Type: Editorial

References (12)

1. Lam SKH, Owen A. Combined resynchronisation and defibrillation therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials. BMJ 2007 doi: 10.1136/bmj.39343.511389.BE.
2. McAlister FA, Tu JV, Newman A, Lee D, Kimber S, Cujec B, et al. How many patients with heart failure are eligible for cardiac resynchronization? Insights from 2 prospective cohorts. Eur Heart J 2006;27:323-9.
3. McAlister FA, Ezekowitz J, Hooton N, Vandermeer B, Dryden DM, Spooner C, et al. The role of cardiac resynchronization therapy in patients with left ventricular systolic dysfunction: a systematic review. JAMA 2007;297:2502-14.
4. Ezekowitz J, Dryden DM, Hooton N, Vandermeer B, Friesen C, Spooner C, et al. Implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction: a systematic review. Ann Intern Med 2007;147:251-62.
5. Stevenson LW. Implantable cardioverter-defibrillators for primary prevention of sudden death in heart failure: are there enough bangs for the bucks? Circulation 2006;114:101-3.
6. Maisel WH. Safety issues involving medical devices: implications of recent implantable cardioverter-defibrillator malfunctions. JAMA 2005;294:955-8.
7. Reynolds MR, Cohen DJ, Kugelmass AD, Brown PP, Becker ER, Culler SD, et al. The frequency and incremental cost of major complications among Medicare beneficiaries receiving implantable cardioverter-defibrillators. J Am Coll Cardiol 2006;47:2493-7.
8. Al-Khatib SM, Lucas FL, Jollis JG, Mallenka DJ, Wennberg DE. The relation between patients' outcomes and the volume of cardioverter-defibrillator implantation procedures performed by physicians treating Medicare beneficiaries. J Am Coll Cardiol 2005;46:1536-50.
9. Teuteberg JJ, Lewis EF, Nohria A, Tsang SW, Fang JC, Givertz MM, et al. Characteristics of patients who die with heart failure and a low ejection fraction in the new millennium. J Cardiac Failure 2006;12:47-53.
10. Ermis C, Seutter R, Zhu AX, Benditt LC, VanHeel L, Sakaguchi S, et al. Impact of upgrade to cardiac resynchronization therapy on ventricular arrhythmia frequency in patients with implantable cardioverter-defibrillators. J Am Coll Cardiol 2005;46:2258-63.
11. Cleland JGF, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure (the cardiac resynchronization-heart failure (CARE-HF) trial extension phase). Eur Heart J 2006;27:1928-32.
12. Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, et al. The effectiveness and cost-effectiveness of cardiac resynchronization therapy (biventricular pacing) for heart failure: a systematic review and economic model. Health Technol Assess (in press).